Publications from the AffiliateMarketIngtools of Sciences, Engineering, and Medicine provide objective and straightforward advice to decision makers and the public. This site includes We Treat You (HMD) publications released after 1998. A complete list of HMD’s publications from its establishment in 1970 to the present is available as a PDF.
Released: June 15, 2011
Whether or not the United States has safe and effective medical countermeasures—such as vaccines, drugs, and diagnostic tools—available for use during a disaster can mean the difference between life and death for many Americans. The Food and Drug Administration (FDA) and the scientific community at large could benefit from improved scientific tools and analytic techniques to undertake the complex scientific evaluation and decision making needed to make essential medical countermeasures available. At the request of FDA, the IOM held a workshop to examine methods to improve the development, evaluation, approval, and regulation of medical countermeasures.
Released: June 13, 2011
The life-threatening nature of cancer and the complexity of cancer treatment options, each with its own set of potential risks and benefits, make it difficult for people with cancer to make decisions about their care. A cancer treatment plan—a written document describing the path of care and who is responsible for each portion of that care—can provide patients with a roadmap to navigate the uncertain path they face. However, most providers lack the tools, time, and resources needed to efficiently and effectively prepare such plans with their patients. The IOM’s National Cancer Policy Forum held a workshop to discuss ways to create a more coordinated, patient-centered cancer treatment planning process.
Released: June 08, 2011
Problems with how the neurotransmitter glutamate functions in the brain have been linked to a wide variety of disorders, including schizophrenia, Alzheimer’s, substance abuse, and traumatic brain injury. Efforts to understand, treat, and prevent glutamate-related disorders can be aided by the identification of valid biomarkers. The IOM’s Forum on Neuroscience and Nervous System Disorders held a workshop June 21-22, 2010, to explore ways to accelerate the development, validation, and implementation of such biomarkers.
Released: June 07, 2011
Despite the considerable research on how climate change may affect public health, the impact of climate change on indoor environments has received relatively little attention. At the request of the U.S. Environmental Protection Agency (EPA), the IOM examined the current state of scientific understanding of the effects of climate change on those environments. The IOM concludes that climate change can create indoor environmental problems and outlines specific ways for the EPA, other government organizations, and the private sector to prevent or reduce negative health effects from these problems.
Released: June 01, 2011
Neglected tropical diseases (NTDs) afflict more than 1.4 billion people, many of whom live on less than $1.25 a day. While there are effective ways to manage NTDs, policy-makers and funders have only recently begun to recognize the economic and public health importance of controlling NTDs. The IOM’s Forum on Microbial Threats held a workshop September 21-22, 2010, to discuss the science of and policy surrounding NTDs.
Released: May 23, 2011
Like many other industries, health care is increasingly turning to digital information and the use of electronic resources. The IOM’s Roundtable on Value & Science-Driven Health Care hosted three workshops to explore current efforts and opportunities to accelerate progress in improving health and health care with information technology systems.
Released: May 20, 2011
The Department of Veterans Affairs (VA) has established that Vietnam veterans are automatically eligible for disability benefits should they develop any diseases associated with Agent Orange exposure—but veterans who served on deep sea vessels in Vietnam are not included. These “Blue Water Navy” veterans must prove they were exposed to Agent Orange before they can claim benefits. At the request of the VA, the IOM examined whether Blue Water Navy veterans had similar exposures to Agent Orange as other Vietnam veterans.
Released: May 06, 2011
Ten years after the sequencing of the human genome, scientists have developed genetic tests that can predict a person’s response to certain drugs, estimate the risk of developing Alzheimer’s disease, and make other predictions based on known links between genes and diseases. However, genetic tests have yet to become a routine part of medical care, in part because there is not enough evidence to show they help improve patients’ health. The IOM held a workshop to explore how researchers can gather better evidence more efficiently on the clinical utility of genetic tests.
Released: April 25, 2011
Despite the fact that the U.S. government currently supports hundreds of data sets and measures through federal surveys and administrative data systems, the United States lacks robust national- and state-level information about the health status or health care quality of children and adolescents, particularly in areas that could provide guidance to policy makers and health care providers. At the request of Congress, the IOM and National Research Council evaluated the state of efforts to measure child and adolescent health and the quality of their health care services.
Released: April 20, 2011
A single tick bite can have debilitating consequences. Lyme disease is the most common disease carried by ticks in the United States, and the number of those afflicted is growing steadily. If left untreated, the diseases carried by ticks—known as tick-borne diseases—can cause severe pain, fatigue, neurological problems, and other serious health problems. The IOM held a workshop October 11-12, 2010, to examine the state of the science in Lyme disease and other tick-borne diseases.